Refine your search
Collections
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Kshirsagar, Sanjay
- Solubility Enhancement of Ritonavir by using Liquisolid Compact Technique
Abstract Views :228 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmaceutics, MET’s Institute of Pharmacy, Adgaon, Nashik, Maharashtra, Affiliated to Savitribai Phule Pune University (SPPU), Pune, IN
2 Adgaon, Nashik, Maharashtra, India, Affiliated to Savitribai Phule Pune University (SPPU), Pune, IN
1 Department of Pharmaceutics, MET’s Institute of Pharmacy, Adgaon, Nashik, Maharashtra, Affiliated to Savitribai Phule Pune University (SPPU), Pune, IN
2 Adgaon, Nashik, Maharashtra, India, Affiliated to Savitribai Phule Pune University (SPPU), Pune, IN
Source
Asian Journal of Pharmacy and Technology, Vol 7, No 4 (2017), Pagination: 189-201Abstract
Novel solubility enhancement technique; liquisolid compact technique is used in present research work. Ritonavir is poorly soluble drug was formulated using Avicel pH 102 and Aerosil 200 as carrier and coating material respectively. Solubility studies were conducted in different liquid vehicles, namely propylene glycol, span 20, PEG 400, tween 20, and PEG 200. From the result of saturation solubility study the liquisolid compacts were formulated using PEG 400 as non volatile vehicle. The ritonavir liquisolid formulations were obtained by allowing liquid vehicle with varying ritonavir concentration to get absorbed onto carrier and coating material taken at different ratio (R=5,10,15,20).Then the ritonavir liquisolid powder system evaluated for flow property determination and then compressed into tablet. Each batch of prepared ritonavir Liquisolid powder compact evaluated for Quality control tests, i.e. uniformity of tablet weight, uniformity of drug content, tablet hardness, friability test, disintegration and dissolution study. Optimized batch of Liquisolid powder compact evaluated for quality control test of tablet along with FTIR, DSC and PXRD study. The tableting properties of the liquisolid compacts were within the acceptable limits and in vitro drug release rate of LS compacts were distinctly higher as compared to directly compressible tablet and pure drug alone. This was due to an increase in wetting properties and surface of drug available for dissolution. FTIR study result indicates that there is no drug excipient interaction..DSC and PXRD study suggested loss of ritonavir crystallinity upon liquisolid formulation, it indicates that drug is held within the power substrate in a solubilized, almost molecularly dispersed state, which lead to enhanced drug solubility. From significant result of solubility of ritonavir, liquisolid technique would be promising solubility enhancement technique for various poorly soluble drugs.Keywords
Ritonavir, Liquisolid Compact, PEG 400, Carrier Material, Coating Material, Poorly Water Soluble Drugs.References
- Patil K. J., Surajj M. Sarode, Sathe B.S., Jain P.V., Jain B.V. (2014), Formulation and evaluation of sustained release tablet of Ritonavir, World Journal of Pharmacy and Pharmaceutical Sciences, 3(4),pp. 857-868.
- Lachmman L, Liberman HA, Konig JL. (1991) The theory and practice of Industrial Pharmacy. 3rdEdn. Vargheese Publishing House, Bombay, pp.430-453
- Sinha S., Ali M., Baboota S., Ahuja A., Kumar A., Ali J., (2010) Solid Dispersion as an Approach for Bioavailability Enhancement of Poorly Water soluble drug Ritonavir, AAPS PharmSciTech,vol.11,pp.518-527.
- Tiong N., Elkordy a., (2009), Effects of liquisolid formulations on dissolution of naproxen, European Journal of Pharmaceutics and Biopharmaceutics, 73, pp.373-384.
- Savjani K.T, Gajjar A.K., and Savjani J.K.,(2012),Drug Solubility: Importance and Enhancement Techniques, International Scholarly Research Network Pharmaceutics,pp.1-10.
- Bindu M.B., Kusum B and David Banji,(2010), Novel strategies for poorly water soluble drugs, international Journal of Pharmaceutical Sciences Review and research,4(3),pp.76-84.
- INDIAN PHARMACOPOEIA 2014,volume III , Government of India , Ministry of Health and Family Welfare, Indian pharmacopoeia commission, Ghaziabad,pp.2677
- https://aidsinfo.nih.gov/drugs/244/ritonavir/34/professional
- https://www.drugbank.ca/drugs/DB00503.
- Nagesh C., Shankaraiah M. M., Attimarad S. L., Patil A. M., Vijay Kumar (2013) ,Improving the solubility and dissolution of Ritonavir by solid dispersion, Journal of Pharmaceutical and Scientific innovation,2(4),pp.30-35.
- Saran K.,Srujan Kumar M., Subrahmanyam K.V,(2013) Enhancement of solubility of Ritonavir by using Solid dispersion Technique, International Journal of innovative Pharmaceutical Sciences and Research,1(2),pp.266-280.
- Dashamukhi R., Kanagala V., Chittimalla A., (2013), Formulation development of Ritonavir tablets containing solid dispersions employing montmorillonite : dissolution rate enhancement, Asian journal of pharmaceutical and clinical research, 6(2), pp.206-208.
- Yogananda R., Chowdary K.P.,(2013), Formulation Development of Ritonavir Tablets Employing B-cyclodextrins, Hydroxy Propyl B-cyclodextrin and Solutaol Hs15, American Journal of PharmTech Research,3,pp.710-718.
- Shah K., Borhade S., Londhe V. (2014), Utilization of co-crystallization for solubility enhancement of a poorly soluble antiretroviral drug-Ritonavir, International journal of pharmacy and pharmaceutical sciences,6( 2),pp.556-558.
- Desai S., Disouza J., Musle K., Hoshmani A.,(2016), Solubility enhancement of Ritonavir by Hot Melt Extrusion, International Journal of Pharmacy and Pharmaceutical Sciences,8(3),pp.309-312 16. Prakash S., Vidyadhara S., Sasidhar R., Abhijit D. and Akhilesh D.(2013),Development and characterization of Ritonavir nanosuspension for oral use, Der Pharmacia Lettre, 5 (6):pp.48-55.
- Balaji A, M.S. Umashankar and B. Kavitha, (2014), Liquisolid technology- a latest review, International Journal of Applied Pharmaceutics, 6(1),pp. 11-19.
- Nagabandi K.V, K. N. Jayaveera, T. Ramarao, (2011) LIQUISOLID Compacts: A Novel Approach to Enhance Bioavailability of Poorly Soluble Drugs, Int J Pharm Bio Sci, Volume 1,Issue 3,89-102 19. Kharwade M., and M Sneha., (2015) ,A Review on Pioneering Technique - Liquisolid Compact and Applications., Research Journal of Pharmaceutical, Biological and Chemical Sciences, 6(2), pp.220-227.
- Kala N. P., Shaikh M. T., Shastri D. H., Shelat P. K., (2014),A Review On Liquisolid Systems, Journal of Drug Delivery and Therapeutics; 4(3),pp. 25-31
- Spireas et al., Liquisolid Systems and Methods of Preparing Same, United States Patent, 5800834, Sep. 1, 1998.
- Spireas S, Sadu S (1998), Enhancement of prednisolone dissolution properties using liquisolid compacts , International journal of pharmaceutics , Elsevier, 166, pp.177-188.
- INDIAN PHARMACOPOEIA, 2007, Government of India, Indian Pharmacopoeia Commission, Ministry Of Health And Family Welfare, Ghaziabad: India, pp.78-80, 177-184, 267-270,495, 897, 1059.
- Srivastava S., Srivastava D., Nimisha, Prajapat V., (2014), Liquisolid Technique for Enhancement of Dissolution Properties of Lornoxicam, Indo Global Journal of Pharmaceutical Sciences, 4(2), pp. 81-90
- Gilvert Banker, Christopher T. Rhodes, Modern Pharmaceutics, 4th ed, Informa health care, pp. 178, 544-551.
- Chella N., Shastria N., Tadikonda R. (2012),Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan, Acta Pharmaceutica Sinica B ,2(5) , pp.502–508
- Karva G. S., Katariya V. R., Shahi S. R., Spray Drying: A Approach for Solubility Enhancement of Ritonavir by Solid Dispersion, International journal of pharmaceutical sciences and Drug Research ,2015, 7( 4) ,pp.321-328.
- Shukla D., chakraborty S., singh S., mishra B.,(2008),Mouth dissolving tablets ii:An overview of evaluation techniques, scientia pharmaceutica,77,pp.327-341.
- Sarraf M., Hussein A., jabbar A.,(2014),Dissolution enhancement of telmisartan by liquisolid compacts, International Journal of Pharmacy and Pharmaceutical Sciences, 6 (2), pp.743-749.
- Asija R., Bhatt S., Asija S., Yadav A., Shah I., (2014), Enhancement of solubility and dissolution of lercanidipine by liquisolid technique, Journal of Chemical and Pharmaceutical Research, 6(6),pp.2680-2686.
- Pavia, D.L., Lampman, G.M., Kriz, G.S. and Vivyan, J.R. 2011, Spectroscopy, 7th ed. New Delhi, Cengage Learning India Pvt. Ltd., pp.26-92.
- Komala D.R., Janga K.Y., Jukanti R., Bandarri S., Vijaygopal M. (2015), Competence of Raloxifene hydrochloride loaded liquisolid compacts for improved dissolution and intestinal permeation, Journal of Drug Delivery Science and Technology, Elsevier, 30, pp.232-241.
- Sanka K., Poienti S., Mohd A., Diwan P.(2014), Improved oral delivery of clonazepam through liquisolid powder compact formulations: In-vitro and Ex-vivo characterization, Powder technology256,Elsevier,pp.336-344.
- Patel J. B. Patel K. J.,(2015), Enhancement of solubility of lornoxicam using novel liquisolid technique, Pharma Science Monitor, 6(2), pp.196-206.
- Lachmman L, Liberman HA, Konig JL. (2013) The theory and practice of Industrial Pharmacy. 4th Edn. Vargheese Publishing House, Bombay, pp.244-247
- Chandel P. Kumar R., Kapoor A.,(2013), Liquisolid Technique: An approach for enhancement of solubility, Journal of drug Delivery and Therapeutics, 3(4), pp.131-137.
- Formulation and Optimization of Silymarin Loaded PLGA Nanoparticle for liver targeting
Abstract Views :221 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmaceutics, MET’s Institute of Pharmacy, Adgaon, Nashik, IN
2 Department of Pharmaceutics, MET’s Institute of Pharmacy, Adgaon, Nashik, Maharashtra, IN
3 MET’s Institute of Pharmacy, Adgaon, Nashik, IN
1 Department of Pharmaceutics, MET’s Institute of Pharmacy, Adgaon, Nashik, IN
2 Department of Pharmaceutics, MET’s Institute of Pharmacy, Adgaon, Nashik, Maharashtra, IN
3 MET’s Institute of Pharmacy, Adgaon, Nashik, IN
Source
Asian Journal of Pharmacy and Technology, Vol 7, No 4 (2017), Pagination: 209-220Abstract
The aim of present study was to prepare silymarin loaded PLGA polymeric nanoparticles for liver targeting by solvent evaporation method. Special attention was devoted to targeted drug delivery to liver and then the controlled release of drug from the polymeric nanoparticles. PLGA were employed as a bio-degradable polymer for targeting and controlled release of drug. The particle size of the resultant PN’s was mainly controlled by the agitation speed during the manufacturing process and polymer concentration. PLGA nanoparticles have the stability problem hence is PVA used as Surfactant as well as Stabilizing agent for the production of stable nanoparticles. Following particle size, zeta potential, and DSC and SEM analysis. The Silymarin nanoparticles were prepared with different ratio of polymer (PLGA), surfactant (PVA) and solvent (acetone) by using solvent evaporation method. The organic phase {drug + polymer (1:1, 1:3, 1:5) + solvent} was added to aqueous phase {water + PVA (1, 2, and 3 %)} and subjected for homogenization with different rpm. The formulation was heated with magnetic stirrer for evaporation of solvent for 2 hrs. After evaporation of solvent, the formulation was centrifuged and supernatant was collected by filtration and dried at room temperature. The formed nanoparticles were evaluated for particle size, entrapment efficiency and in vitro release. The Nanoparticle was obtained having Particle Size in between 422.4-294.3 nm. Entrapment Efficiency in between 74.30-99.8% and % drug release in between 73.53-98.67% which follows the sustained release behavior. From given Data it concludes that Nanoparticle containing PLGA exhibiting excellent sustained release characteristics and Entrapment efficiency and also Good particle Size. Hence After stability studies all formulations were found to be physically and chemically stable.Keywords
Silymarin, PLGA, Polymeric Nanoparticle, PVA, Control Release.References
- NCCAM. Research Report: National Center for Complementary and Alternative Medicine. 2003. Hepatitis C and Complementary and Alternative Medicine: 2003 Update; pp. 2–20.
- Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, et al. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology. 2008; 47: 605–612.
- Strader DB, Bacon BR, Lindsay KL, La Brecque DR, Morgan T, Wright EC, Allen J, et al. Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol. 2002; 97:2391–2397.
- Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DY. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology. 2007; 132:1925–1936.
- Freedman ND, Curto TM, Morishima C, Seeff LB, Goodman ZD, Wright EC, Sinha R, Everhart JE. the HALT-C Trial Group. Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial. Alimentary Pharmacology and Therapeutics. 2010 2 NOV 2010.
- Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, Reddy KR, Wahed AS, et al. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol.2010;50:434–449.
- Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, Doo E, et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA. 2012; 308:274–282
- Wagner H. Plant constituents with antihepatotoxic activity. In: Beal JL, Reinhard E eds. Natural Products as Medicinal Agents. Stuttgart: Hippokrates-Verlag; 1981.
- Bosisio E, Benelli C, Pirola O, et al. Effect of the flavanolignans of Silybummarianum L. on lipid peroxidation in rat livermicrosomes and freshly isolated hepatocytes. Pharmacol Res 1992; 25:147-154.
- Baer-Dubowska W, Szaefer H, Drajka-Kuzniak V. Inhibition of murine hepatic cytochrome P450 activities by natural and synthetic phenolic compounds. Xenobiotica 1998; 28:735-743.
- Halim AB, el-Ahmady O, Hassab-Allah S, et al. Biochemical effect of antioxidants on lipids and liver function in experimentally- induced liver damage. Ann ClinBiochem 1997; 34:656-663.
- Campos R, Garido A, Guerra R, et al. Silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver. Planta Med 1989; 55:417-419.
- Fiebrich F, Koch H. Silymarin, an inhibitor of lipoxygenase. Experentia 1979; 35:150-152.
- Dehmlow C, Erhard J, de Gischolar_main H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996; 23:749-754.
- Fantozzi R, Brunelleschi S, Rubino A, et al. FMLP-activated neutrophils evoke histamine release from mast cells. Agents Actions 1986; 18:155-158.
- Dehmlow C, Murawski N, de Gischolar_main H, et al. Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. Life Sci 1996; 58:1591-1600.
- De La Puerta R, Martinez E, Bravo L. Effect of silymarin on different acute inflammation models and on leukocyte migration. J Pharm Pharmacol 1996; 48:968-970.
- Sonnenbichler J, Zetl I. Biochemical effects of the flavanolignanesilibinin on RNA, protein and DNA synthesis in rat livers. In: Cody V, Middleton E, Harbourne JB, eds. Plant Flavonoids in Biology and Medicine: Biochemical, Pharmacological, and Structure-Activity Relationships. New York, NY; 1986:319-331.
- Fuchs EC, Weyhenmeyer R, Weiner OH, et al. Effects of silibinin and of a synthetic analogue on isolated rat hepatic stellate cells and myofibroblasts.Arzneimittelforschung 1997; 26:643-649.
- Deak G, Muzes G, Lang I. Immunomodulator effect of silymarin therapy in chronic alcoholic liver diseases. OrvHetil 1990:131:1291-1292, 1295-1296. [Article in Hungarian]
- Lang I, Nekam K, Gonzalez-Cabello R. Hepatoprotective and immunological effects of antioxidant drugs. Tokai J ExpClin Med 1990; 15:123-127.
- Vyas and Khar, Targeted and controlled drug delivery, first edition 2002
- Jaya, A., et al. 2011, Targeting: New potential carriers for targeted drug delivery system, 8 (2), pp. 117-123.
- Fabienne, D., et al. 2010, Review: To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery, Journal of Control Release, 148, pp. 135–146.
- Pathak, Y. and Thassu, D. 2009, Drug delivery nanoparticles formulation and characterization, Drugs and Pharmaceutical Science Series, Informa health care, New York: USA, vol-191, pp. 4, 16-18, 56-59, 22-23, 27-28.
- Kamel, A.O., et al. 2007, Preparation and characterization of acyclovir nanoparticles by double emulsion technique, EJBS, 23, pp.166-175.
- Park, J., et al. 2009, PEGylated PLGA nanoparticles for the improved delivery of doxorubicin, Nanomedicine: NBM, 5, pp. 410-418.
- Machado, S.R. and Evangelista, R.C. 2010, Development and characterization of Cefoxitin, J. Basic Appl. Pharm. Sci., 31 (3), pp. 193-202.
- Kumar, P.V. and Jain, N.K. 2007, Suppression of agglomeration of ciprofloxacin-loaded human serum albumin nanoparticles, AAPS Pharm Sci Tech, 8 (1), pp. E1-E6.
- Zhang, J.Y., et al. 2011, Preparation of the albumin nanoparticle system loaded with both paclitaxel and sorafenib and its evaluation in vitro and in vivo, J. Microencapsul., 28(6), pp.528–536.
- Takashima, Y., etal. 2007, Spray-drying preparation of microparticles containing cationic PLGA nanospheres as gene carriers for avoiding aggregation of nanospheres, Int. J Pharma., 343, pp. 262-269.
- Pandi, M., et al. 2011, Isolation and detection of taxol, an anticancer drug produced from Lasiodiplodiatheobromae, an endophytic fungus of the medicinal plant Morindacitrifolia, AJB, 10 (8), pp. 1428-1435.